Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer

Nicole Golob-Schwarzl1,2 · Christina Wodlej1,3 · Florian Kleinegger1,4 · Margit Gogg-Kamerer1 · Anna Maria Birkl-Toeglofer1 · Johannes Petzold1 · Ariane Aigelsreiter1 · Michael Thalhammer5 · Young Nyun Park6 · Johannes Haybaeck1,3,7,8

Received: 9 May 2019 / Accepted: 16 September 2019 / Published online: 4 October 2019
© The Author(s) 2019

Abstract

Background  Gallbladder cancer (GBC) is a rare neoplasia of the biliary tract with high mortality rates and poor prognosis. Signs and symptoms of GBC are not specific and often arise at late stage of disease. For this reason, diagnosis is typically made when the cancer is already in advanced stages, and prognosis for survival is less than 5 years in 90% of cases. Biomarkers to monitor disease progression and novel therapeutic alternative targets for these tumors are strongly required. Commonly, dysregulated protein synthesis contributes to carcinogenesis and cancer progression. In this case, protein synthesis directs translation of specific mRNAs, and, in turn, promotes cell survival, invasion, angiogenesis, and metastasis of tumors. In eukaryotes, protein synthesis is regulated at its initiation, which is a rate-limiting step involving eukaryotic translation initiation factors (eIFs). We hypothesize that eIFs represent crossroads in the development of GBC, and might serve as potential biomarkers. The study focus was the role of eIF6 (an anti-association factor for the ribosomal subunits) in GBC.

Methods  In human GBC samples, the expression of eIF6 was analyzed biochemically at the protein (immunohistochemistry, immunoblot analyses) and mRNA levels (qRT-PCR).

Results  High levels of eIF6 correlated with shorter overall survival in biliary tract cancer (BTC) patients (n = 28). Immunohistochemical data from tissue microarrays (n = 114) demonstrated significantly higher expression levels of eIF6 in GBC compared to non-neoplastic tissue. Higher eIF6 expression on protein (immunoblot) and mRNA (qRT-PCR) level was confirmed by analyzing fresh frozen GBC patient samples (n = 14). Depletion of eIF6 (using specific siRNA-mediated knockdown) in Mz-ChA-2 and TFK-1 cell lines inhibited cell proliferation and induced apoptosis.

Conclusion  Our data indicates that eIF6 overexpression plays a major role in the translational control of GBC, and indicates its potential as a new biomarker and therapeutic target in GBC.

Keywords  Gallbladder cancer · Eukaryotic translation initiation factor 6 · Biomarker

Electronic supplementary material  The online version of this article (https://doi.org/10.1007/s00432-019-03030-x) contains supplementary material, which is available to authorized users.

Abbreviations

AKT  Protein kinase B
BSA  Bovine serum albumin
BTC  Biliary tract cancer

5 Department of General Surgery, Medical University of Graz, Graz, Austria
6 Department of Pathology, Yonsei University, College of Medicine Soul, Seoul, South Korea
7 Department of Pathology, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39210 Magdeburg, Germany
8 Department of Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria
The translation initiation process is monitored by eukaryotic initiation factors (eIFs). They might serve as tumor suppressors or promote carcinogenesis and tumor progression in different types of cancer (Spilka et al. 2013; Silvera et al. 2010). The eIF signaling cascade is mainly regulated via the PI3K/AKT/mTOR pathway due to its pivotal role in regulating cell growth and proliferation. This pathway operates as sensor, for instance, for nutrition-energy availability and adapts gene expression, ribosome biogenesis, and protein translation to surrounding conditions of the cells. Uncontrolled/hyperactivated PI3K/AKT/mTOR signaling leads to dysregulated protein synthesis, which contributes to carcinogenesis and cancer progression (Golob-Schwarzl et al. 2017; Jackson et al. 2010; Spilka et al. 2013; Engelmann 2009; Liu et al. 2009). Protein translation regulation mainly takes place at the initiation phase which is also the rate-limiting step of protein synthesis in eukaryotes. The initiation starts with the formation of the 43S ribosome pre-initiation complex, consisting of the 40S small ribosomal subunit, methionine tRNAi and various eIFs, followed by the recruitment of the 43S ribosome complex to the 5′UTR region of the mRNA via the cap-binding complex eIF4F (Golob-Schwarzl et al. 2017; Spilka et al. 2013; Silvera et al. 2010). The eIF4F complex comprises the scaffold protein eIF4G, the cap-binding protein eIF4E, and the ATP-dependent helicase eIF4A.

The last step of translation initiation is the formation of the mature 80S ribosome by joining the 60S subunit. To prevent untimely binding of the 60S ribosomal subunit to the 40S ribosomal subunit, the 25 kDa protein eIF6 plays an important role as the anti-association factor. Since no pseudogenes nor gene duplications of eIF6 can be found, it can be proposed that there is a strong evolutionary pressure for tight control of the protein expression and concentration, underlying the importance of proper functioning of eIF6 (Parsyan et al. 2011; Parsyan 2014). eIF6 binds to 60S ribosomal subunits already in the nucleus and releases them into the cytoplasm after phosphorylation by mitogens or growth factors (Golob-Schwarzl et al. 2017; Spilka et al. 2013). Therefore, it can be found in the nucleus and in the cytoplasm. Approximately 30% of eIF6 are localized in the nucleus, and 70% of eIF6 are located in the cytoplasm (Zhu et al. 2017). As interaction of the 60S with the 40S subunit is impaired by eIF6, translation initiation is blocked (Spilka et al. 2013; Zhu et al. 2017). Many studies state that eIF6 is rate limiting in the regulation of translation (Golob-Schwarzl et al. 2017; Finch et al. 2011; Gartmann et al. 2010; Miluzio et al. 2011; García-Márquez et al. 2015). Furthermore, eIF6 also plays an important role in the biogenesis of the 60S ribosome (Golob-Schwarzl et al. 2017; Spilka et al. 2013).

Dysfunction of translation control is probably the endpoint of oncogenic pathways that support cellular transformation and tumor development (Silvera et al. 2010). However, most of these pathways are hyperactivated and...
pro-oncogenic in tumors (Parsyan et al. 2011; Loreni et al. 2013). eIF6 was found to be overexpressed in various cancer types, like colorectal cancer, ovarian serous carcinoma, acute promyelocytic leukemia, non-small cell lung cancer and in head and neck cancer (Golob-Schwarzl et al. 2017; Spilka et al. 2013; Parsyan et al. 2011; Gantenbein et al. 2018).

In this study, we investigated the involvement of various eIF subunits, focusing on eIF6 in GBC. For this purpose, we used analyses like immunohistochemistry and immunoblotting to characterize the eIF6 protein expression levels. qRT-PCR was used for gene expression studies, as well as The Cancer Genome Atlas dataset to correlate gene expression with overall survival. Finally, we assessed the therapeutic potential of targeting eIF6 by performing siRNA-mediated knockdown experiments in two biliary tract cancer (BTC) cell lines (TFK-1, Mz-ChA-2).

**Methods**

**Ethics statement**

The collection and use of human-derived gallbladder specimens were approved by the Ethics Committee of the Medical University of Graz, Austria, according to the ethical guidelines of the 1975 Declaration of Helsinki (28-294 ex 15/16) and the Institutional Review Board of the Severance Hospital (no. 4-2014-0421, Seoul, South Korea). All samples and medical data used in this study were irreversibly anonymized and their clinical and pathological data are listed in Tables 1 and 2.

**Tissue microarrays (TMAs)**

114 formalin-fixed, paraffin-embedded patient samples were retrospectively collected from the University Hospital of Seoul. Hematoxylin–eosin-stained (H/E) slides were reviewed by an experienced, board-certified pathologist (J.H.), who confirmed the diagnoses and identified the areas of tumor and non-neoplastic tissue for each tissue microarray core. The usage of patient samples for the generation of TMAs was approved by the local ethics committees (No. 28-294 ex 15/16 and 4-2014-0421). Tissue cores of 1.2 mm in diameter were punched out from the chosen tumor areas and embedded as TMA in a fresh paraffin block according to a specific pattern. Tissue sections were cut (4 µm) and placed on adhesive-coated glass slides followed by immunohistochemical analysis. Clinical and pathological data are listed in Table 1.

**Immunohistochemistry (IHC)**

The protein expression of eIF6 was analyzed by immunohistochemical staining. IHC was performed on a Ventana Immunostainer XT (Ventana Medical Systems, Tucson, USA) by heat-induced epitope retrieval (HIER) in cell conditioning solution for 30 min. For detection, the ultra-VIEW universal DAB Detection Kit (Ventana Medical Systems, Tucson, USA) was used. Each core was semi-quantitatively
scored, and the intensity score was assessed as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining and 3 = strong staining. Additionally, stained tumor cells were recorded in a percentage ranging from 0 to 100% (TIS).

**Human gallbladder cancer patient samples**

Human GBC samples and non-neoplastic tissue (NNT) were obtained at the Diagnostic and Research Institute of Pathology, Medical University of Graz, Austria or the BioBank Graz, Austria. Informed consent was obtained from all patients. All tissue samples were acquired during surgery, immediately snap frozen in liquid nitrogen, and stored at −80 °C until protein or RNA extraction. The cohort description is listed in Table 2.

**Protein extraction and immunoblot**

For generation of protein lysates, frozen tissue samples were homogenized with a MagNA Lyser homogenizer (Roche Diagnostics, Risch-Rotkreuz, Switzerland) and lysed in Nonidet-P40-based lysis buffer (0.05 M Tris–HCl, 0.15 M NaCl, 0.5% NP-40, 0.1 mM Pefabloc, 1 mM DTT, complete Mini EDTA-free, PhosSTOP). Protein concentrations were determined using Bradford protein assay (BioRad Protein Assay Dye Reagent; BioRad Laboratories GmbH, Munich, Germany). 30 µg of total protein lysate were loaded onto sodium dodecyl sulfate (SDS)-polyacrylamide gels (30% Acrylamide/Bisacrylamid solution; ROTH, Karlsruhe, Germany), subjected to electrophoresis in mini-vertical electrophoresis units (Hoefer Inc, Richmond, USA), and blotted onto PVDF membranes (Immobilin-P Transfer Membrane; Millipore, Massachusetts, USA) using a Semi-Dry Blotting Unit (SCIE-PLAS; Cambridge, England). The membranes were blocked with 5% non-fat dried milk (AppliChem; Darmstadt, Germany) in TBS supplemented with 0.1% Tween (TBST) for 1 h at room temperature. The primary antibody eIF6 (1:1000, #PA5-31066, Thermo Fischer Scientific Inc., Massachusetts, USA) was diluted in TBST containing 5% BSA and incubated at 4 °C overnight. The membranes were washed with TBST, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (anti-rabbit 1:5000; GE Healthcare Life Science, Buckinghamshire, UK). Proteins were visualized using the chemiluminescence Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Science, Buckinghamshire, UK). Proteins were visualized using the chemiluminescence Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Science, Buckinghamshire, UK).

### Table 2 Clinical and pathological characteristics of 26 patient cryo samples

| Adenocarcinoma of the gallbladder | Number (n = 14) | %     |
|----------------------------------|----------------|-------|
| Gender                           |                |       |
| Female                           | 9              | 64.3  |
| Male                             | 5              | 35.7  |
| Age (± SD)                       | 70.4 (8.5)     |       |
| Subtype adenocarcinoma           |                |       |
| Adenosquamous                    | 4              | 28.6  |
| Tubular                          | 4              | 28.6  |
| Mucinous                         | 1              | 7.1   |
| Tubulo-papillary                 | 4              | 28.6  |
| Mixed                            | 1              | 7.1   |
| Grading                          |                |       |
| 1                                | 7              | 50    |
| 2                                | 6              | 42.9  |
| 3                                | 1              | 7.1   |
| NNT                              | n = 12         |       |
| Gender                           |                |       |
| Female                           | 2              | 16.7  |
| Male                             | 10             | 83.3  |
| Age (± SD)                       | 57.8 (8.1)     |       |
Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated from snap-frozen human GBC tissue and NNT using TRIzol Reagent (Life Technologies; Woolston, UK) followed by phenol–chloroform extraction. siRNA-transfected cells were washed three times with PBS, scraped off with PBS and lysed with TRIzol Reagent. Total RNA (1 µg) was reversely transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, USA) according to the manufacturer’s instructions (GeneAmp 9700 Thermocycler, Applied Biosystems; Foster City, USA). For gene expression analyses, the Power SYBR Green PCR Master Mix Kit (Applied Biosystems, Foster City, USA) was used in a QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems, Foster City, USA). GAPDH was found to be the most stable endogenous control using NormFinder, and relative gene expression levels were calculated using the $2^{\Delta\Delta CT}$ method.

Cell culture

The cell line TFK-1 was cultured in RPMI-1640 supplemented with 10% FBS and antibiotics (penicillin 100 U/ml; streptomycin 100 µg/ml). Mz-ChA-2 cells were cultured in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 1 × MEM non-essential amino acids (Gibco, Life Technologies, Darmstadt, Germany) and antibiotics (penicillin 100 U/ml; streptomycin 100 µg/ml).

Both cell lines were cultured at 37 °C in a humid atmosphere with 5% CO$_2$ and passaged when 90% confluency was reached (use of Trypsin–EDTA 0.05%, Life Technologies, California, USA). To exclude mycoplasma contamination, both cell lines were routinely checked using PromoKine PCR Mycoplasma Test Kit (Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria). STR profiling (PowerPlex 16HS System, Promega, Madison USA) was done to verify cell lines. Both cell lines (TFK-1 and Mz-ChA-2 cells) were obtained from the American Type Culture Collection (ATCC).

siRNA transfection

For eIF6 knockdown, two target sequences were used: eIF6-1 (20 nM, Hs_ITGB4BP_5, 5′-CTGCTTTGGCACA GCTCACAA-3′, #SI0309633, QIAGEN, Hilden, Germany) and eIF6-2 (20 nM, HS_ITGB4BP_6, 5′-CTG GTGCATCCCAAGACTTCA-3′, #SI03099768 QIA GEN, Hilden, Germany). A scrambled siRNA (SC) construct (20 nM, Allstars negative control siRNA #1027280, QIAGEN, Hilden, Germany) was used as negative control. Transfection experiments were performed using Metafectene®SI+ transfection reagent (Biontex, Munich, Germany) according to the manufacturer’s instructions. For the transfection 1x SI buffer, Metafectene® SI+ and siRNA were mixed in 6-well plates. After an incubation of 15 min at room temperature, 1x10$^5$ cells were added to each well. Cells with transfection mix were cultured at 37 °C in a humidified atmosphere of 5% CO$_2$. Cells were harvested after incubation for 48 h and 72 h. Three independent experiments were performed.

MTT assay

Transfected cells and controls were seeded in 96-well plates (1 x 10$^4$ cells/well) and cultivated without antibiotics for 48 h and 72 h. Metabolic activity of cells was determined on the basis of mitochondrial conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, Missouri, USA) to insoluble formazan. Therefore, cells were incubated with 5.5 mg/ml MTT for 2 h at 37 °C. The supernatant was discarded, and cells were lysed with 3% SDS. Formazan crystals were dissolved in 0.05 M isopropanol/HCl for 15 min at room temperature under vigorous shaking. Absorption was measured at 570 nm (Synergy™4, BioTek, Winooski, USA). Each sample was carried out in sixfold determination, and three independent experiments were performed.

Apoptosis

Apoptotic cells were detected using YO-PRO™-1 (Thermo Fisher Scientific, Massachusetts, USA) reagent. siRNA-transfected and control cells were seeded in 96-well plates (1 × 10$^4$ cells/well). After 48 h and 72 h cells were incubated with YO-PRO™-1 for 15 min at 37 °C, the supernatant was removed, and cells were washed with PBS. After excitation (485 nm), emission was measured at 535 nm. Each assay was performed in sixfold determination, and three independent experiments were carried out.

Colony formation assay

Transfected cells and controls were seeded into six-well plates (500 cells/well) and cultivated over 2 weeks. The medium was changed every 3 days. After cultivation, cells were washed three times with PBS followed by fixation in 4% paraformaldehyde (Sigma-Aldrich, Missouri, USA). Fixed cells were stained with freshly prepared Giemsa solution (1:10 with ddH$_2$O) (Sigma-Aldrich, Missouri, USA) for 20 min. Afterwards, cells were rinsed with distilled water; colonies were analyzed using an inverse microscope (Nikon TMS—Inverted Microscope, Tokyo, Japan). Three independent experiments were carried out.
Statistical analysis

The Cancer Genome Atlas (TCGA) public dataset including 28 CCC subjects was analyzed to identify the association between gene expression stratified by the median and survival. Kaplan–Meier curves were generated using the survival R package. The log-rank test was applied to test for association of survival and gene expression. All results were expressed as mean ± standard deviation (SD). Differences between groups were assessed using Student’s *t* test or Mann–Whitney *U* test based on data distribution. Results of the cell culture experiments were statistically tested using one- or two-way ANOVA with Bonferroni post-test. A *p* value < 0.05 was considered as statistically significant. Statistical analysis and graph generation were performed using GraphPad PRISM version 5.0 (GraphPad software Inc., La Jolla, CA, USA).

Results

**eIF6 is a marker of gallbladder cancer (GBC) with bad prognosis**

We determined eIF6 expression levels in patient-derived GBC tissue and NNT by immunohistochemical staining (IHC) of tissue microarray (TMA) sections to address the prognostic potential of eIF6 (Fig. 1a–d). Clinical data of patients analyzed by IHC are listed in Table 1. 114 GBC patient samples were analyzed, and respective adjacent NNT served as controls. eIF6 staining was mainly observed in the cytoplasm but also in the nucleus (Fig. 1c, d). The tissue intensity score (TIS) of cytoplasmic eIF6 was higher in GBC tissue in the cytosol compared to NNT (Fig. 1e, f). However, there were no changes regarding eIF6 immunoreactivity manifested in the nucleus compared to NNT (Fig. 1e, f).

To examine whether eIF6 protein levels, compared to NNT, are also upregulated in cryo material of gallbladder tumor tissue, total protein lysates of 14 GBC tissue specimens and 12 non-neoplastic gallbladder tissue specimens were prepared. The patients’ characteristics for the cryo material are listed in Table 2. These lysates were analyzed by immunoblotting and revealed overexpression of eIF6 in GBC samples (Fig. 2a) when compared to NNT. Densitometric evaluation (eIF6/GAPDH) of all samples analyzed by ImageJ is outlined in Fig. 2b and revealed significantly higher expression of eIF6 compared to NNT (*p* < 0.05). This patient cohort was also analyzed for *EIF6* mRNA expression levels using qRT-PCR which revealed differences (*p* = 0.1106) (Fig. 2c). These data suggest that eIF6 may play an important role during tumorigenesis of GBC.

**High expression of eIF6 correlates with shorter survival and poor prognosis of BTC patients**

Based on the results shown above, we investigated the correlation between the expression of eIF6 and patient overall survival. Therefore, an in silico analysis including 28 patients of The Cancer Genome Atlas (TCGA) database was performed. Tests for statistical significance were carried out with the log-rank test. Kaplan–Meier curves were generated to assess a potential association of *EIF6* expression with overall survival in biliary tract cancer (BTC) patients. Higher expression of *EIF6* in BTC was associated with a poorer overall survival compared to low expression of *EIF6* (*p* = 0.0193) (Fig. 2d).

Additionally, other eIF subunits (e.g., 1, 1AX, 1B, 2a, 3A, 3C, 3H, 5, 4E, 4G1, 4G2, and 4G3) were investigated for their influence on BTC patients’ overall survival (Supplementary Figure S1 and S2). Higher expression of eIF4E in BTC showed a significant poorer overall survival compared to low expression of eIF4E (*p* = 0.040) (Supplementary Figure S2A). There was no significant difference for the eIF subunits 1, 1AX, 1B, 2a, 3A, 3C, 3H, 5, 4G1, 4G2 and 4G3. These findings suggest that eIF6 might have a different functional role and might serve as a novel prognostic marker for the overall survival of BTC patients.

**In vitro knockdown of eIF6 reduces cell growth and proliferation, and increase apoptosis**

Based on the results of the basic characterization of GBC patient-derived tissue (Figs. 1, 2), eIF6 was identified as a novel factor significantly overexpressed in GBC, which is why this protein might represent a potential target for future therapeutic interventions.

To evaluate the consequences of reduced eIF6 levels, Mz-ChA-2 and TFK-1 cell lines were transfected with eIF6 targeting siRNA. Knockdown efficiency was evaluated by immunoblot 48 and 72 h post-transfection. eIF6 knockdown was highly efficient (between 60 and 80% at both time points analyzed) in Mz-ChA-2 cells independent of whether the siRNA constructs were used individually (eIF6-1 and eIF6-2) or in combination (eIF6-1 + 2) (Fig. 3a). In TFK-1 cells, single siRNA constructs and the siRNA pool reduced eIF6 levels to 60–80% compared to non-targeting scrambled siRNA (Fig. 4a). Densitometrical evaluations of eIF6 knockdown in both cell lines are shown in Figs. 3b and 4b.

Additionally, knockdown efficiency was evaluated by qRT-PCR 48 and 72 h post-transfection (Figs. 3c, 4c). Analysis of *EIF6* mRNA levels in Mz-ChA-2 and TFK-1 cells after silencing revealed a reduction of about 70–80% compared to non-targeting scrambled siRNA (SC). The mRNA levels of *EIF6* in Mz-ChA-2 and TFK-1 cells were reduced.
Colony formation assay after 48 and 72 h eIF6 knock-down was investigated with Mz-ChA-2 and TFK-1 cells (Figs. 3d, 4d). Compared to control cells (cells, MOCK and SC), both transfected cell lines evidently had fewer colonies after 3 weeks of cultivation.

In Mz-ChA-2 and TFK-1 cells, cell viability was significantly ($p < 0.005$) reduced in comparison to transfection with SC (Figs. 3e, 4e). After 72 h of transfection in Mz-ChA-2 and TFK-1, cell viability was significantly reduced by 70% by all eIF6 targeting constructs compared to SC control (Figs. 3e, 4e).

Fig. 1 eIF6 is overexpressed in GBC compared to NNT. a Representative hematoxylin–eosin (H/E) staining was reviewed to confirm the diagnoses and to identify the areas of formalin-fixed, paraffin-embedded non-neoplastic tissue (NNT) for each tissue microarray core. Scale bars: 500 µm and 50 µm. b Representative hematoxylin–eosin (H/E) staining was reviewed to confirm the diagnoses and to identify the areas of formalin-fixed, paraffin-embedded tumors for each tissue microarray core. Scale bars: 500 µm and 50 µm. c Representative IHC pictures of eIF6-stained non-neoplastic tissue (NNT). eIF6 is mainly located in the cytoplasm of NNT GBC tissue. eIF6 is evident in both the nucleolus and cytoplasm of tumor cells. Scale bars: 500 µm and 50 µm. d Representative IHC picture of nuclear eIF6-stained GBC tissue. eIF6 is evident in both the nucleolus and cytoplasm of tumor cells. Scale bars: 500 µm and 50 µm. e Tissue intensity scores (TIS) revealed stronger staining intensity of eIF6 in the cytoplasm in GBC patients compared to NNT. f Tissue intensity score (TIS) revealed no changes in the staining intensity of eIF6 in the nucleolus in GBC patients compared to NNT.

by 50–70% compared to SC after 72 h after transfection (Figs. 3c, 4c).

Colony formation assay after 48 and 72 h eIF6 knock-down was investigated with Mz-ChA-2 and TFK-1 cells (Figs. 3d, 4d). Compared to control cells (cells, MOCK and SC), both transfected cell lines evidently had fewer colonies after 3 weeks of cultivation.

In Mz-ChA-2 and TFK-1 cells, cell viability was significantly ($p < 0.005$) reduced in comparison to transfection with SC (Figs. 3e, 4e). After 72 h of transfection in Mz-ChA-2 and TFK-1, cell viability was significantly reduced by 70% by all eIF6 targeting constructs compared to SC control (Figs. 3e, 4e).
Conversely, the apoptosis rates of Mz-ChA-2 and TFK-1 cells were increased by targeting eIF6 compared to transfection with SC after 48 and 72 h (Figs. 3f, 4f). After 72 h of transfection in Mz-ChA-2 and TFK-1, apoptosis was significantly increased by 20–40% in all siRNA constructs compared to SC (Figs. 3f, 4f).

Discussion

Gallbladder cancer is a rare neoplasia of the biliary tract that differs from other cancers of the digestive tract. Signs and symptoms of GBC are not specific and often arise late in the clinical course of disease. For this reason, diagnosis is typically made when the cancer is already in advanced stages, and prognosis for survival is less than 5 years in 90% of cases. Furthermore, GCB is characterized by its resistance to radio and chemotherapy (Randi et al. 2006). Biomarkers to monitor disease progression and novel therapeutic alternative targets for these tumors are strongly required.

eIFs are involved in the translation of growth factors, proteins influencing cell cycle, and growth, as well as apoptosis and malignant transformation. mTOR pathway members and eIFs are overexpressed in malignancies, such as squamous cell carcinoma of the head and neck, cancer of the lung, thyroid, breast and other cancer types (Wang et al. 2012;
Fig. 3 Knockdown of eIF6 in Mz-ChA-2 cell line. a Representative immunoblots of successful knockdown of eIF6 with siRNA after 48 and 72 h in Mz-ChA-2 cells. b Densitometrical analysis of eIF6 signals normalized to GAPDH, which served as loading control. In Mz-ChA-2 cells, eIF6 protein levels are significantly (***p < 0.001) decreased after 48 and 72 h, compared to scrambled siRNA-transfected condition. c mRNA levels of EIF6 in transfected Mz-ChA-2 cells analyzed by qRT-PCR and normalized to GAPDH mRNA levels. Three independent experiments were carried out. Bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis: one-way ANOVA with Bonferroni post-test. d Representative picture of colony formation assay of induced eIF6 knockdown after 48 h and 72 h post-transfection in Mz-ChA-2 cell line. e Cell viability of Mz-ChA-2 cells transfected with eIF6 siRNA after 48 h and 72 h (***p < 0.001). f Graphs show apoptosis rates after eIF6 knockdown compared to SC after 48 h and 72 h (***p < 0.001). Three independent experiments were carried out. Bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis: one-way ANOVA with Bonferroni post-test.
Fig. 4 Knockdown of eIF6 in TFK-1 cell line. a Representative immunoblots of successful knockdown of eIF6 with siRNA after 48 and 72 h in TFK-1 cell line. b Densitometrical analysis of eIF6 signals normalized to GAPDH, which served as loading control. In TFK-1 cells, eIF6 protein levels are decreased after 48 and 72 h post-transfection, compared to scrambled siRNA-transfected condition. c mRNA levels of EIF6 in transfected TFK-1 cells analyzed by qRT-PCR and normalized to GAPDH mRNA levels. Three independent experiments were carried out. Bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis: one-way ANOVA with Bonferroni post-test. d Representative colony formation assay of eIF6 knockdown induced 48 h and 72 h post-transfection in TFK-1 cell line. e Cell viability of TFK-1 cells transfected with eIF6 siRNA after 48 h and 72 h (**p < 0.001). f Graphs show apoptosis rates after eIF6 knockdown compared to SC after 48 h and 72 h (***p < 0.001). Three independent experiments were carried out. Bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis: two-way ANOVA with Bonferroni post-test.
Gantenbein et al. 2018). However, data on eIFs in GBC are still limited.

The in silico analysis of The Cancer Genome Atlas (TCGA) database revealed a significant influence of eIF4E on overall survival of BTC patients. eIF4E is part of the eIF4F complex, interacts with the mRNA and facilitates the recruitment of the 40S ribosomal subunit. mTOR directly phosphorylates the 4E-binding protein (4E-BP), which are inhibitors of eIF4E, to relieve translational suppression. Hyperactivation of the mTOR pathway occurs in majority of the cancers, which results in increased eIF4E activity. Thus, translational control via eIF4E acts as a convergence point for hyperactivation and promotes tumorigenesis (Siddiqui and Sonenberg 2015). Targeting eIF4E is currently under investigation in many cancer types and might represent a target in GBC therapy (Siddiqui and Sonenberg 2015). eIF4E seems to be an important part of the tumorigenesis GBC patients.

eIF6 affects the maturation of 60S ribosomal subunits (Sanvito et al. 2000) as well as formation of the 80S ribosome as anti-association factor (Miluzio et al. 2009), and can be found in the nucleolus as well as in the cytoplasm. eIF6 was found to be overexpressed in various cancer types, like metastatic colorectal cancer (CRC) (Golob-Schwarzl et al. 2017) or non-small cell lung cancer (Gantenbein et al. 2018). eIF6 expression was reported to limit cell growth and transformation (Basu et al. 2001). Regulation of eIF6 is neither controlled transcriptionally via c-Myc nor post-transcriptionally via the PI3K/AKT/mTOR signaling (Chendrimada et al. 2007). The specific molecular mechanisms underlying the role of eIF6 in these processes remain unclear (Parsyan et al. 2011; Siddiqui and Sonenberg 2015; Gantenbein et al. 2018; Miluzio et al. 2011; García-Márquez et al. 2015; Sanvito et al. 2000; Biffo et al. 1997; Sanvito et al. 1999).

Our study is the first to give evidence that eIF6 is overexpressed in GBC compared to non-neoplastic gallbladder tissue, and that it is a predictor for overall survival in GBC. Genetic interference with eIF6 by RNAi technique reduced cell proliferation and induced apoptosis in vitro. Our results highly suggest that eIF6 might be an important biomarker in GBC. Therefore, in pathologic examinations of the gallbladder, RNA or protein quantification of eIF6 could possibly predict the survival of GBC patients (Golob-Schwarzl et al. 2017; Sanvito et al. 2000; Miluzio et al. 2015; Flavin et al. 2008; Rosso et al. 2004). Thus, directly targeting eIF6 by reducing its expression or inhibiting its activity might improve therapeutic efficacy.

eIF6 overexpression was found in human CRC but not in non-neoplastic tissue, indicating a potential new therapeutic target (Golob-Schwarzl et al. 2017; Sanvito et al. 2000). Patients with ovarian serous adenocarcinomas showed eIF6 overexpression and a correlation with patients’ overall survival (Golob-Schwarzl et al. 2017; Flavin et al. 2008).

TCGA data set displayed an influence of eIF6 on patients’ overall survival in GBC. Moreover, the IHC staining of GBC for eIF6 revealed its overexpression in the cytoplasm of gallbladder tumor cells, whereas staining intensity and density were less in non-neoplastic gallbladder tissue. This increase in cytoplasmic eIF6 levels in human FFPE tissue specimens was already reported in CRC, ovarian serous adenocarcinoma, and pleural mesothelioma (Golob-Schwarzl et al. 2017; Miluzio et al. 2015; Flavin et al. 2008). However, there was no change in the eIF6 expression in the nucleus when comparing GBC tissue and the non-neoplastic cells.

Mortality of a total knockout of eIF6 was distinguished in a mouse model for MYC-stimulated lymphomagenesis where littermates of eIF6−/− mice were not viable. In eIF6+/− heterozygous knockout mice, tumor-free survival was observed, suggesting that eIF6 might limit tumor progression (Gartmann et al. 2010). In Saccharomyces cerevisiae, depletion of TIF6, the yeast homologue for eIF6, led to reduced cell proliferation and viability (Busa et al. 2001).

Since eIF6 turned out to be a novel promising target on protein and mRNA level for GBC, we performed knockdown experiments to investigate this factor in more detail. After successful knockdown of eIF6, the proliferation rate and the colonogenicity of TFK-1 and Mz-ChA-2 cells were significantly reduced. This confirms previously published data, where after eIF6 knockdown eIF6 was significantly reduced in HCT116 cells and led to reduced proliferation and colonogenicity (Golob-Schwarzl et al. 2017). Many cellular phenomena were related to alteration in activities of cap-dependent and internal ribosomal entry site (IRES)-driven translation during programmed cell death. Even though activated, eIF4F cooperates with c-MYC to promote malignant transformation. This effect is mediated by the power of eIF4F to block MYC-induced apoptosis through translational activation of negative regulators of the apoptotic machinery (Lin et al. 2009; Ruggiero 2009; Polunovsky et al. 1996; Wendel et al. 2004). In our present study, we also analyzed apoptosis levels after knockdown of eIF6, and revealed a significant increase after 48 h and 72 h in transfected TFK-1 and Mz-ChA-2 cells. However, the nucleolar cytoplasmic relevance and function of eIF6 in, as well as its contribution to, tumorigenesis raise questions that are difficult to answer. Hence, the relevance of eIF6 in tumorigenesis seems to be context dependent and remains to be fully elucidated.

Conclusion

In conclusion, we suggest that eIF6 might serve as a prognostic biomarker for overall survival in GBC patients, and that its regulation could serve as a potential new therapy approach in GBC. eIF6 can might be used in the future as a
marker in immunohistochemistry. Still, there is a need for future investigations of eIF6 expression in GBC to determine whether eIF6 drives gallbladder carcinogenesis.

Nevertheless, still much effort for further investigation on eIF6 in GBC needs to be taken. Consequently, the aim of our study was to define novel therapeutic targets or potential new biomarkers to facilitate diagnosis and to improve the dismal prognosis associated with this highly malignant disease.

Acknowledgements Open access funding provided by Medical University of Graz. The research leading to these results was supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115234], the resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and kind contributions from EFPIA companies (to J.H.). We thank Prof. Kai Breuhabn from the University Hospital of Heidelberg, Germany for providing the TFK-1 cell line and Prof. Alexander Knuth from the University of Zurich, Switzerland for the Mz-ChA-2 cell line. This work has been carried out with K1 COMET Competence Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology (BMVIT); the Federal Ministry of Science, Research and Economy (BMWFW); Land Styria (Department 12, Business and Innovation); the Styrian Business Promotion Agency (SFG); and the Vienna Business Agency. The COMET program is executed by the FFG (to J.H.).

Author contribution NGS, CW and FK are responsible for the concept and design of this study. NGS, CW, MKG, AMBT, JP, YNP, and FK performed experiments and procedures. NGS, CW, and FK wrote the article. MT, AA, and JH provided resources and tissue. JH devised the study, designed and interpreted the experiments, and edited the manuscript. JH acquired funding for conducting the entire study. All authors contributed to and approved the final manuscript.

Funding The authors disclose no competing financial interests.

Compliance with ethical standards

Conflict of interest All authors declared that have no conflicts of interest.

Ethical approval The collection and use of human-derived gallbladder specimens were approved by the Ethics Committee of the Medical University of Graz, Austria, according to the ethical guidelines of the 1975 Declaration of Helsinki (28-294 ex 15/16) and the Institutional Review Board of the Severance Hospital (no. 4-2014-0421, Seoul, South Korea).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Basu U, Si K, Warner JR, Maitra U (2001) The Saccharomyces cerevisiae TIF6 gene encoding translation initiation factor 6 is required for 60S ribosomal subunit biogenesis. Mol Cell Biol 21(5):1453–1462
Biffo S, Sanvito F, Costa S, Preve L, Pignatelli R, Spinardi L, Marchioli PC (1997) Isolation of a novel beta4 integrin-binding protein (p27 (BBP)) highly expressed in epithelial cellls. J Biol Chem 272(48):30314–30321
Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RII, Liebhaber SA, Pasquinelli AE, Shiekhattar R (2007) MicroRNA silencing through RISC recruitment of eIF6. Nature 447(7146):823–828
Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562
Finch AJ, Hilcenko C, Basse N, Drynan LF, Goyenechea B, Menne TF, González Fernández A, Simpson P, D’Santos CS, Arends MJ, Donadieu J, Bellanén-Chatolet C, Costanzo M, Boone C, McKenzie AN, Freund SMV, Warren AJ (2011) Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman–Diamond syndrome. Genes Dev 25(9):917–929
Flavin RJ, Smyth PC, Finn SP, Laios A, O’toole SA, Barrett C, Ricciardi S, Brina D, Biffo S (2008) Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 21(6):676–684
Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Gogg-Kamerer M, Lindenmann J, Fink-Neuböck N, Bricic L, Gollowitsch F, Stacher-Priehe R, Rolf J, Hoffmann J, Silvestri A, Reichard C, Reinhard C, Peherl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Satller W, Haybaecj J (2018) Eukaryotic translation initiation factor 6 impacts NSCLC. Eur J Cancer 101:165–180
García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015a) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678
García-Márquez A, Gijsbers A, de la Mora E, Sánchez-Puig N (2015b) Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem 290(29):17669–17678
Gartmann M, Blau M, Armache JP, Mielke T, Topf M, Beckmann R (2010) Mechanism of eIF6-mediated inhibition of ribosomal subunit joining. J Biol Chem 285(20):14848–14851
Golob-Schwarzl N, Schweiger C, Kollier C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofner AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Kell M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaecj J (2017) Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget 8(60):101224–101243
Jackson RJ, Hellen CUT, Pestova TV (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11(2):113–127
Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC (2013) AKT/mTOR substrate P70S6 K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 6:1373–1384
Lin CJ, Malina A, Pelletier J (2009) c-Myc and eIF4F constitute a feedback loop that regulates cell growth: implications for anticancer therapy. Cancer Res 69(19):7491–7494
Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(3):2145–2162
Loreni F, Mancino M, Biffo S (2013) Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogen 33:2145–2156
Miluzio A, Beugnet A, Volta V, Biffo S (2009) Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep 10(5):495–465

© Springer
Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011a) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775

Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S (2011b) Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19(6):765–775

Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015a) Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. Oncotarget 6(35):37471–37485

Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S (2015b) Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo. Oncotarget 6(35):37471–37485

Parsyan A (2014) Translation and its regulation in cancer biology and medicine. Springer, Berlin (ISBN 978-94-017-9077-2)

Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC (2011) mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 12(4):235–245

Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, Bitterman PB (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiological expressed or deregulated Myc. Mol Cell Biol 16(11):6573–6581

Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118(7):1591–1602

Rosso P, Cortesina G, Sanvito F, Donadini A, Di Benedetto B, Biffo S, Marchisio PC (2004) Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck 26(5):408–417

Ruggiero D (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69(23):8839–8843

Sanvito F, Piatti S, Villa A, Bossi M, Lucchini G, Marchisio PC, Biffo S (1999) The beta4 integrin interactor p27 (BBP/eIF6) is an essential nuclear matrix protein involved in 60S ribosomal subunit assembly. J Cell Biol 144(5):823–837

Sanvito F, Vivoli F, Gambini S, Santambrogio G, Catena M, Viale E, Veglia F, Donadini A, Biffo S, Marchisio PC (2000) Expression of a Highly Conserved Protein, p27 BBP, during the Progression of Human Colorectal Cancer. Cancer Res 60(3):510–516

Shaffer EA (2008) Gallbladder cancer: the basic. Gastroenterol Hepatol 4(1):737–741

Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A (2017) Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23(22):3978–3998

Siddiqui N, Sonenberg N (2015) Signaling to eIF4E in cancer. Biochem Soc Trans 43(5):763–772

Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10(4):254–266

Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136(4):731–745

Spilka R, Ernst C, Kuldeep Mehta A, Haybaeck J (2013) Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett 340(1):9–21

Wang XL, Cai HP, Ge JH, Su XF (2012) Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 18(20):2540–2544

Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332–337

Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thomas H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J (2007) Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67(8):3794–3800

Zhang F, Xiang S, Cao Y, Li M, Ma Q, Liang H, Li H, Ye Y, Zhang Y, Jiang L, Hu Y, Zhou J, Wang X, Zhang Y, Nie L, Liang X, Gong W, Liu Y (2017) EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3 K-AKT signaling pathway. Cell Death Dis 8(6):e2868

Zhu W, Li GX, Chen HL, Liu XY (2017) The role of eukaryotic translation initiation factor 6 in tumors. Oncol Lett 14(1):3–9

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.